Sonidegib is a product used to treat a certain type of skin cancer (basal cell carcinoma). In July 2015, the US FDA (Food and Drug Administration) approved sonidegib (Odomzo®; Novartis, New Jersey, USA) for the treatment of adult patients with basal cell carcinoma. in situ progression (BCC). Read more to understand more about the uses, indications and precautions when using Sonidegib.

Odomzo medicine contains the active ingredient sonidegib with a strength of 200mg, which is made in the form of tablets. The drug is indicated in the treatment of basal cell carcinoma. However, when using Odomzo, there may be some unwanted side effects such as muscle pain, muscle tension, rash, difficulty breathing...